BridgeMD
Budesonide as a treatment for inflammation in stomach complaints.
EU CTIS ID: 2024-517035-43-00
What this study is testing
The effect of Budesonide on duodenal eosinophilia in functional dyspepsia patients.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Functional dyspepsia patients with meal related symptoms (postprandial distress syndrome) as described by the Rome IV criteria
- Patients aged between 18 and 70 years inclusive
- Male or female patients
You likely can't join if
- Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable to participate in the study
- Patients who take drugs altering gastric emptying, anti-inflammatory drugs, acid suppressive drugs or some drugs altering the CYP3A4 metabolism
- Patients with major change in diet in the last 3 months
- Females who are pregnant or lactating
- Patients not capable to understand or be compliant with the study.
- Patients with any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years
See the full eligibility criteria
- Functional dyspepsia patients with meal related symptoms (postprandial distress syndrome) as described by the Rome IV criteria
- Patients aged between 18 and 70 years inclusive
- Male or female patients
- Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable to participate in the study
- Patients who take drugs altering gastric emptying, anti-inflammatory drugs, acid suppressive drugs or some drugs altering the CYP3A4 metabolism
- Patients with major change in diet in the last 3 months
- Females who are pregnant or lactating
- Patients not capable to understand or be compliant with the study.
- Patients with any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years
- Patients presenting with predominant symptoms of irritable bowel syndrome (IBS) or of gastro-esophageal reflux disease (GERD)
- Patients with diabetes mellitus, celiac disease, lupus, scleroderma or other systemic auto-immune disease
- Patients with eosinophilic esophagitis or eosinophilic gastroenteritis
- Patients with active H. Pylori infection (or < 6 months after eradication)
- Patients with proven food allergy
- Patients with an organic gastro-intestinal disease of history of gastrointestinal surgery other than appendectomy
- Patients with known sever impaired liver dysfunction
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.